---
# Section Metadata
slug: exit-potential
component: ExitPotential.astro
componentPath: src/layouts/sections/narratives/ExitPotential.astro
order: 4
category: returns
lastUpdated: 2024-12-18

# Display Configuration
title: Exit Potential
subtitle: Two proven paths to liquidity for longevity investments
eyebrow: Returns

# Hero Statistics (3 inline stats)
heroStats:
  - stat: "$2B+"
    label: Longevity IPOs in 2023
    citationKey: kh56wu

  - stat: "17.9%"
    label: Anti-aging Market CAGR
    citationKey: s0d2yp

  - stat: "$5B+"
    label: Startup Funding in 2023
    citationKey: kh56wu

# IPO Path Details
ipoPath:
  title: IPOs in Public Markets
  icon: chart-up
  description: Biotech IPOs remain a core liquidity event, especially for companies with differentiated clinical data in age-related disease.
  points:
    - title: Quality Over Quantity
      text: The post-2021 correction led to a disciplined IPO market focused on clinical-stage, de-risked assets.
      citationKey: ct5ss8

    - title: 100% Clinical-Stage
      text: By 2023, all US biotech IPOs had clinical-stage assets, with roughly one-third at Phase III.
      citationKey: ct5ss8

    - title: Mainstream Theme
      text: Longevity-focused biotechs raised over $2 billion via IPOs in 2023 alone, signaling aging biology as investable.
      citationKey: kh56wu

    - title: Data-Driven Stories
      text: Investors reward platforms that pair bold aging biology with credible, near-term milestones.
      citationKey: "2y30de"

# M&A Path Details
maPath:
  title: Acquisitions by Big Pharma
  icon: building
  description: Large pharma companies facing patent cliffs are increasingly acquiring longevity-adjacent assets to sustain growth.
  points:
    - title: Massive Market Growth
      text: Global anti-aging therapeutics projected to grow from $5.7B (2024) to $34.6B by 2035.
      citationKey: s0d2yp

    - title: M&A as Core Return Driver
      text: Institutional investors expect continued M&A as pharma uses acquisitions to access innovative platforms.
      citationKey: ct5ss8

    - title: Strategic Fit
      text: Longevity mechanisms intersect with existing pharma markets—cardiometabolic, oncology, ophthalmology.
      citationKey: "4729z2"

    - title: VC Capital Precursor
      text: Longevity VC funds raised over $3B in 2023, seeding future acquisition targets.
      citationKey: kh56wu

# Market Growth Projection
marketGrowth:
  from: "$5.7B"
  to: "$34.6B"
  period: "2024-2035"
  cagr: "17.9%"
  citationKey: s0d2yp

# Deal Example
dealExample:
  title: Example Deal Structure
  subtitle: Pharma-Senolytics Acquisition Model
  rationale:
    - Large pharma seeking next-generation assets that modify fundamental aging biology
    - Senolytics address shared mechanisms across multiple age-related diseases
    - One asset with potential across several multi-billion-dollar indications
  terms:
    - label: Target
      value: Clinical-stage senolytics company

    - label: Buyer
      value: Top-10 global pharma

    - label: Upfront
      value: $500M-$1B cash

    - label: Biobucks
      value: $2B-$4B milestones
  citationKey: "4729z2"

# Closing CTA
closing:
  eyebrow: The Opportunity
  headline: Exits Don't Require Full Lifespan Extension
  text: Credible age-related disease indications are sufficient for pharma-scale exits

# Citations
citations:
  kh56wu:
    title: "Longevity Biotech Market Growth: How Fast Is Anti-Aging Science Advancing"
    url: https://patentpc.com/blog/longevity-biotech-market-growth-how-fast-is-anti-aging-science-advancing-new-stats
    source: PatentPC
    publishedDate: "2025-11-14"

  "2y30de":
    title: "Longevity Startup Funding Sees Fewer Moonshots, But Plenty Of..."
    url: https://news.crunchbase.com/venture/longevity-startup-funding-2025-newlimit-data/
    source: Crunchbase News
    publishedDate: "2025-11-17"

  ct5ss8:
    title: Biotech IPOs in 2025
    url: https://www.wellington.com/en/insights/biotech-ipos-in-2025
    source: Wellington Management
    publishedDate: "2024-08-22"

  "4729z2":
    title: 13 anti-aging biotech companies leading longevity in 2025
    url: https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies/
    source: Labiotech
    publishedDate: "2025-10-27"

  s0d2yp:
    title: Top 10 Global Companies in Anti-aging Therapeutics Market 2025
    url: https://www.sphericalinsights.com/blogs/top-10-global-companies-in-anti-aging-therapeutics-market-2025-strategic-overview-future-trends-2024-2035
    source: Spherical Insights
    publishedDate: "2025-08-19"
---

# Exit Potential: IPOs & M&A

## What This Section Communicates

This is the **returns/exit** slide. It demonstrates that longevity investments have clear, proven paths to liquidity through both IPOs and pharma acquisitions.

## Visual Structure

1. **Hero Opening** (min-height 70vh)
   - "Returns" eyebrow
   - Large headline: "Exit Potential"
   - Supporting subtitle
   - Three inline hero stats
   - Scroll indicator

2. **Two Exit Paths** (side-by-side cards)
   - Section badge: "Exit Paths"
   - Headline: "Two Proven Routes to Liquidity"
   - Two large cards:
     - **IPO Path**: Icon, title, description, 4 points with citations
     - **M&A Path**: Icon, title, description, 4 points with citations

3. **Market Growth Visualization**
   - Section badge: "Market Opportunity"
   - Visual showing $5.7B → $34.6B growth
   - Arrow with CAGR percentage
   - Clean gradient background

4. **Deal Example**
   - Section badge: "Deal Structure"
   - Two-column layout:
     - **Strategic Rationale**: Bullet list
     - **Illustrative Terms**: Label/value pairs
   - Amber/gold accent color

5. **Closing CTA**
   - "The Opportunity" eyebrow
   - Key message: Full lifespan extension not required
   - Gradient glow effect

6. **Sources Section**
   - Citations from Wellington, Crunchbase, Labiotech, etc.

## Theming

Color scheme: Green tones for "returns/growth" messaging, amber for deal structure.

- **Light**: Clean green accents on white
- **Dark**: Emerald/teal glows on void
- **Vibrant**: Intense green gradients and glow effects

## Key Messages

1. **IPO Viability**: $2B+ in longevity IPOs in 2023
2. **M&A Appetite**: Pharma needs assets for patent cliff replacement
3. **Market Growth**: 17.9% CAGR through 2035
4. **Pragmatic Exits**: Disease indications, not immortality

## Animation

- Hero stats reveal with delays
- Exit path cards fade up sequentially
- Market growth arrow animates
- Deal cards slide in

## Dependencies

- `@lib/citations/types` - Citation type definitions
- `@components/citations/InlineCitation.astro` - Popover citations
- `@components/citations/Sources.astro` - Sources list
